Boston Scientific (BSX) Earns Daily Media Sentiment Score of 0.13

News articles about Boston Scientific (NYSE:BSX) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Boston Scientific earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.2438949190619 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news stories that may have effected Accern Sentiment’s analysis:

Shares of Boston Scientific (NYSE:BSX) traded up $0.70 during mid-day trading on Wednesday, reaching $26.81. 8,048,659 shares of the company’s stock were exchanged, compared to its average volume of 9,880,000. Boston Scientific has a 1 year low of $23.29 and a 1 year high of $29.93. The company has a market capitalization of $36,820.00, a PE ratio of 383.00, a PEG ratio of 1.90 and a beta of 0.81. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The firm had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.39 billion. During the same period last year, the firm earned $0.30 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. analysts forecast that Boston Scientific will post 1.37 EPS for the current year.

A number of brokerages recently weighed in on BSX. Canaccord Genuity began coverage on shares of Boston Scientific in a report on Tuesday, October 24th. They issued a “buy” rating and a $36.00 price target for the company. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price target for the company in a report on Friday, October 20th. BMO Capital Markets raised their price target on shares of Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, October 27th. SunTrust Banks set a $34.00 price target on shares of Boston Scientific and gave the company a “buy” rating in a report on Tuesday, October 31st. Finally, Barclays reissued a “buy” rating and issued a $32.00 price target on shares of Boston Scientific in a report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $31.00.

In other news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $26.66, for a total transaction of $413,230.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Maulik Nanavaty sold 15,568 shares of Boston Scientific stock in a transaction on Friday, February 9th. The stock was sold at an average price of $25.38, for a total transaction of $395,115.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 177,032 shares of company stock worth $4,648,733. Insiders own 0.74% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Boston Scientific (BSX) Earns Daily Media Sentiment Score of 0.13” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/14/boston-scientific-bsx-earns-daily-media-sentiment-score-of-0-13.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply